Lynn Seely

Chief Executive Officer, Lyell Immunopharma

Search every verified Lynn Seely interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a February 2017 interview at the BIO CEO & Investor Conference, Lynn Seely, then President and CEO of Myovant Sciences, discussed the company's focus on women's health and endocrinology, particularly uterine fibroids and endometriosis. She stated that women's health has been "largely ignored by big pharma" and described Myovant's oral medical therapy, which she said lowers estrogen and could potentially reduce heavy menstrual bleeding in uterine fibroid patients without invasive surgery. Seely noted that the company was in Phase 3 testing for uterine fibroids and initiating Phase 3 trials for endometriosis in the first half of 2017. Seely also reflected on her prior experience at Medivation, where she oversaw development of the prostate cancer drug Xtandi, and described that role as relevant to her work at Myovant. She identified the main challenge of her first CEO position as managing a compressed timeline, including taking the company public in one of the largest biotech IPOs of 2016, building the team, establishing an office in San Francisco, and preparing to launch five Phase 3 clinical trials. She expressed hope that, with successful trials, Myovant could become a commercial company by 2020.